Press Releases
Ripple Science and Curavit Clinical Research Sign Partnership Agreement to Accelerate Decentralized Clinical Trials (DCTs)
Apr 14, 2022, 18:52 PM
by
Ripple Enterprise software to be deployed as part of the digital transformation in clinical
trials spearheaded by Curavit.
ANN ARBOR, MI- April 12, 2022 – Ripple Science, a digital clinical trial software
company, today announced a partnership with Curavit Clinical Research
(Curavit) to deploy Ripple Enterprise, the company’s newly expanded software
platform, to support several digital therapeutic decentralized clinical trials. Ripple
is a natural fit for Curavit’s digital-first disruptive approach to engaging patients,
conducting research, and accelerating time to market of new discoveries,
especially in the exploding field of digital therapeutics.
“We are hyper-focused on the unique needs of DTx manufacturers, with nearly
half of our rapidly growing customer base running studies on novel digital
therapeutics,” said Joel Morse, CEO of Curavit, the industry’s first virtual CRO.
“Ripple offers scalable, patient-centric functionality that aligns with our
decentralized clinical trial service offering for emerging DTx companies.”
Ripple Enterprise is the world’s only direct-to-patient software platform designed
to support decentralized, virtual, and hybrid clinical trials. Designed and audited
to 21 CFR Part 11, HIPAA, GDPR and SOC2 standards, Ripple Enterprise enables
the entire clinical trial industry to adopt digital clinical trial workflows driving
down costs and expanding access to a more diverse pool of patients.
“We’re excited to partner with Curavit which is on the cutting edge of the digital
transformation in clinical trials,” said Peter Falzon, CEO of Ripple Science. “This
partnership is our largest contract to date and validates our strategic decision to
invest in Ripple Enterprise as a response to customer demand for DCT enabling
software at enterprise scale.”
About Curavit:
Curavit Clinical Research is a full-service, virtual contract research organization
(VCRO), focused on designing and executing digital-first decentralized clinical
trials (DCTs). Founded in 2020 by experts with decades of experience in
technology and clinical research, Curavit leverages emerging technologies in
digital health, cloud computing, and data science to recruit, engage, and monitor
diverse patient populations without borders, bringing trials to patients in the
cloud. Curavit’s digital-first DCTs improve timelines, reduce costs, yield real-world
data, and increase patient access for therapies more effective across diverse
populations. For more information, visit www.curavitclinicalresearch.com.
About Ripple Science:
Ripple Science, a clinical trial technology company, is leading the digital
transformation in clinical trials with a direct-to-patient software platform that
was built by researchers for researchers. By improving the user experience,
increasing regulatory compliance, and further connecting the ecosystem through
digital innovation and technology, Ripple delivers real-time transparency,
game-changing efficiencies, and more secure workflows & data sharing,
concerning all aspects of patient engagement from first contact to last patient
visit, whether virtual or in-person.
Ripple Science was named a Top 50 Company to Watch in 2021 by Michigan
Celebrates Small Businesses and recognized in 2022 by Purpose Jobs and
Cronicle Tech News as one of the fastest growing health tech startup companies
in Ann Arbor.
company, today announced a partnership with Curavit Clinical Research
(Curavit) to deploy Ripple Enterprise, the company’s newly expanded software
platform, to support several digital therapeutic decentralized clinical trials. Ripple
is a natural fit for Curavit’s digital-first disruptive approach to engaging patients,
conducting research, and accelerating time to market of new discoveries,
especially in the exploding field of digital therapeutics.
“We are hyper-focused on the unique needs of DTx manufacturers, with nearly
half of our rapidly growing customer base running studies on novel digital
therapeutics,” said Joel Morse, CEO of Curavit, the industry’s first virtual CRO.
“Ripple offers scalable, patient-centric functionality that aligns with our
decentralized clinical trial service offering for emerging DTx companies.”
Ripple Enterprise is the world’s only direct-to-patient software platform designed
to support decentralized, virtual, and hybrid clinical trials. Designed and audited
to 21 CFR Part 11, HIPAA, GDPR and SOC2 standards, Ripple Enterprise enables
the entire clinical trial industry to adopt digital clinical trial workflows driving
down costs and expanding access to a more diverse pool of patients.
“We’re excited to partner with Curavit which is on the cutting edge of the digital
transformation in clinical trials,” said Peter Falzon, CEO of Ripple Science. “This
partnership is our largest contract to date and validates our strategic decision to
invest in Ripple Enterprise as a response to customer demand for DCT enabling
software at enterprise scale.”
About Curavit:
Curavit Clinical Research is a full-service, virtual contract research organization
(VCRO), focused on designing and executing digital-first decentralized clinical
trials (DCTs). Founded in 2020 by experts with decades of experience in
technology and clinical research, Curavit leverages emerging technologies in
digital health, cloud computing, and data science to recruit, engage, and monitor
diverse patient populations without borders, bringing trials to patients in the
cloud. Curavit’s digital-first DCTs improve timelines, reduce costs, yield real-world
data, and increase patient access for therapies more effective across diverse
populations. For more information, visit www.curavitclinicalresearch.com.
About Ripple Science:
Ripple Science, a clinical trial technology company, is leading the digital
transformation in clinical trials with a direct-to-patient software platform that
was built by researchers for researchers. By improving the user experience,
increasing regulatory compliance, and further connecting the ecosystem through
digital innovation and technology, Ripple delivers real-time transparency,
game-changing efficiencies, and more secure workflows & data sharing,
concerning all aspects of patient engagement from first contact to last patient
visit, whether virtual or in-person.
Ripple Science was named a Top 50 Company to Watch in 2021 by Michigan
Celebrates Small Businesses and recognized in 2022 by Purpose Jobs and
Cronicle Tech News as one of the fastest growing health tech startup companies
in Ann Arbor.
